VYNE Therapeutics Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q4 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
VYNE Therapeutics Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q4 2024.
  • VYNE Therapeutics Inc. Debt-to-equity for the quarter ending December 31, 2024 was 17.4 %, a 24.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q4 2024 17.4 -5.72 -24.8% Dec 31, 2024
Q3 2024 13.4 -25.5 -65.5% Sep 30, 2024
Q2 2024 14.2 -14.2 -50% Jun 30, 2024
Q1 2024 16.3 -5.53 -25.4% Mar 31, 2024
Q4 2023 23.1 +5.06 +28.1% Dec 31, 2023
Q3 2023 38.9 +17.8 +84.5% Sep 30, 2023
Q2 2023 28.4 +1.86 +7% Jun 30, 2023
Q1 2023 21.8 -23.8 -52.1% Mar 31, 2023
Q4 2022 18 -38.7 -68.2% Dec 31, 2022
Q3 2022 21.1 -52.4 -71.3% Sep 30, 2022
Q2 2022 26.6 -63.6 -70.5% Jun 30, 2022
Q1 2022 45.6 -45.9 -50.2% Mar 31, 2022
Q4 2021 56.7 -59.3 -51.1% Dec 31, 2021
Q3 2021 73.5 -57.3 -43.8% Sep 30, 2021
Q2 2021 90.2 -15.2 -14.4% Jun 30, 2021
Q1 2021 91.5 +3.74 +4.26% Mar 31, 2021
Q4 2020 116 +70.3 +153% Dec 31, 2020
Q3 2020 131 +116 +785% Sep 30, 2020
Q2 2020 105 +94.6 +883% Jun 30, 2020
Q1 2020 87.7 +80 +1028% Mar 31, 2020
Q4 2019 45.8 +38.5 +527% Dec 31, 2019
Q3 2019 14.8 +6.21 +72.6% Sep 30, 2019
Q2 2019 10.7 Jun 30, 2019
Q1 2019 7.78 Mar 31, 2019
Q4 2018 7.31 Dec 31, 2018
Q3 2018 8.56 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.